Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 2/20 | 0.53 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.53 |
| ▸ | GPR84 | Q9NQS5 | 8/20 | 0.50 |
| ▸ | NAAA | Q02083 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8006383 | 1.00 | FFAR1 (0.53) | FFAR1FFAR4GPR84NAAANFKB1 | |
| SCHEMBL19066841 | 1.00 | FFAR1 (0.53) | FFAR1FFAR4GPR84NAAANFKB1 | |
| SCHEMBL7991094 | 1.00 | FFAR1 (0.53) | FFAR1FFAR4GPR84NAAANFKB1 | |
| SCHEMBL8418227 | 0.93 | CA2 (0.51) | FFAR1FFAR4GPR84NAAANFKB1 | |
| SCHEMBL296649 | 0.93 | NAAA (0.55) | NAAAEPHX1CA2TSHRFAAH | |
| SCHEMBL296648 | 0.93 | NAAA (0.55) | NAAAEPHX1CA2TSHRFAAH | |
| SCHEMBL5179238 | 0.93 | NAAA (0.55) | NAAAEPHX1CA2TSHRFAAH | |
| SCHEMBL20535742 | 0.93 | NAAA (0.55) | NAAAEPHX1CA2TSHRFAAH | |
| SCHEMBL730516 | 0.93 | NAAA (0.55) | NAAAEPHX1CA2TSHRFAAH | |
| SCHEMBL20512287 | 0.93 | NAAA (0.55) | NAAAEPHX1CA2TSHRFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116196225-A | W/O/W emulsion cosmetic composition and preparation method thereof | 韩国科玛株式会社 | 2023-06-02 | — | — | CN | disclosed |
| US-20130280175-A1 | WATER-CONTAINING ANTIPERSPIRANT COMPOSITIONS WITH IMPROVED WHITE MARK PROTECTION | HENKEL AG & CO. KGAA (DE) | 2013-10-24 | — | — | US | disclosed |
| US-8496939-B2 | An adjuvant is used in vaccine formulation, comprising a polymeric emulsifier Arlacel\" or ATLOX\"; stable, low viscosity | INTERVET INTERNATIONAL B.V. (NL) | 2013-07-30 | — | — | US | disclosed |
| US-7989008-B2 | Cosmetic preparations designed to reduce unsightly cellulite | MENARINI INDUSTRIE FARMACEUTICHE RIUNITE S.R.L. (IT) | 2011-08-02 | — | — | US | disclosed |
| EP-1557152-B1 | COSMETICS EXCELLENT IN TEXTURE AND OIL-DISPERSIBILITY | IDEMITSU TECHNOFINE CO LTD (JP) | 2011-01-26 | — | — | EP | disclosed |
| US-20100112104-A1 | COSMETIC PREPARATIONS DESIGNED TO REDUCE UNSIGHTLY CELLULITE | A.MENARINI INDUSTRIE FARMACEUTICHE RIUNITE S.R.L. (IT) | 2010-05-06 | — | — | US | disclosed |
| US-20100016324-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CELLULITE | MENARINI RICERCHE S.P.A. (IT) | 2010-01-21 | — | — | US | disclosed |
| EP-2139862-A1 | COSMETIC PREPARATIONS DESIGNED TO REDUCE UNSIGHTLY CELLULITE | A. MENARINI INDUSTRIE FARMACEUTICHE RIUNITE S.R.L. (IT) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008116602-A1 | COSMETIC PREPARATIONS DESIGNED TO REDUCE UNSIGHTLY CELLULITE | A.MENARINI INDUSTRIE FARMACEUTICHE RIUNITE S.R.L. (IT) | 2008-10-02 | — | — | WO | disclosed |
| US-20080050398-A1 | Composition Comprising Beta-Defensin 2 | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (HENKEL KGAA) (DE) | 2008-02-28 | — | — | US | disclosed |
| US-20080004283-A1 | Pharmaceutical Compositions for the Treatment of Cellulite | MENARINI RICERCHE S.P.A. (IT) | 2008-01-03 | — | — | US | disclosed |
| EP-1824463-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CELLULITE | Menarini Ricerche S.p.A. (IT) | 2007-08-29 | — | — | EP | disclosed |
| US-20070190004-A1 | Substances with a probiotic action used in deodorants | HENKEL KOMMDITGESELLSCHAFT AUF AKTIEN (HENKEL KGAA) (DE) | 2007-08-16 | — | — | US | disclosed |
| EP-1738803-A1 | Inhibitors of staphylococcus hominis in deodorants and antiperspirants | Henkel Kommanditgesellschaft auf Aktien (DE) | 2007-01-03 | — | — | EP | disclosed |
| US-20060140992-A1 | Cosmetics excellent in texture and oil-dispersibility | IDEMITSU TECHNOFINE CO., LTD. (JP) | 2006-06-29 | — | — | US | disclosed |
| WO-2006063714-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CELLULITE | MENARINI RICERCHE S.P.A. (IT) | 2006-06-22 | — | — | WO | disclosed |
| US-20040071716-A1 | Injectable water-in-oil emulsions | INTERVET INTERNATIONAL B.V. (NL) | 2004-04-15 | — | — | US | disclosed |
| US-6569409-B1 | Suncreen cosmetic; thickening hydrophilic/hydrophobic copolymer is stearyl acrylate/methacrylic acid copolymer | SOCIETE L'OREAL S.A. (FR) | 2003-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040071716-A1 | Injectable water-in-oil emulsions | ALOX15, ALOX12, ALOX5 | FFAR1 300/4885FFAR4 250/4885GPR84 57/4885 |
| US-20100112104-A1 | COSMETIC PREPARATIONS DESIGNED TO REDUCE UNSIGHTLY CELLULITE | CUTA, TYR, CYP51A1 | FFAR1 493/4885FFAR4 469/4885GPR84 4394/4885 |
| US-20070190004-A1 | Substances with a probiotic action used in deodorants | DAGLA, DGAT1, DGAT2 | FFAR1 53/4885FFAR4 30/4885GPR84 326/4885 |
| US-20130280175-A1 | WATER-CONTAINING ANTIPERSPIRANT COMPOSITIONS WITH IMPROVED WHITE MARK PROTECTION | PWWP2B, CUTA, DSG1 | FFAR1 1096/4885FFAR4 1146/4885GPR84 3075/4885 |
| US-20080050398-A1 | Composition Comprising Beta-Defensin 2 | DLK1, DSG1, DBNL | FFAR1 2598/4885FFAR4 2250/4885GPR84 2539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.